Back to Stakeholders
Categories

1 domain / 2 areas / 1 specialization

Apeiron Investment Group

Also known as: Apeiron

Data updated

Abu Dhabi, United Arab Emirates

Apeiron Investment Group is a discretionary investment firm founded and owned by Christian Angermayer. Its website says it manages approximately $7 billion and operates with teams in New York, London, Berlin, Abu Dhabi, and Malta, with a primary focus on the U.S. market.

It matters in the psychedelic ecosystem because Apeiron has been a recurring backer of atai Life Sciences, including co-leading atai's $125 million Series C financing in 2020 and its $50 million private placement financing in 2025. Apeiron's own website also describes psychedelics as a key part of its investment story and says it has been instrumental in the renaissance of psychedelics as treatments for mental health issues.

Investor Context

Venture Capital

Investment Context

This stakeholder is listed as a Family Office within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.

Public Portfolio Examples

Apeiron Investment Group appears to be a multi-strategy family office style platform with direct investments across the company lifecycle, including incubating, accelerating, scaling, and supporting public companies. It describes itself as generally opportunistic while highlighting biotech, fintech and crypto, deep tech, experiences, real estate, and natural resources as areas of focus, and it explicitly frames psychedelic medicine as one of its defining themes through its longstanding association with atai Life Sciences.

Investor Type

Family Office

Geographic Scope

Global

Psychedelic Focus

Explicit Psychedelic Focus

Engagement

Active

Investment Stage Focus

SeedSeries A/BGrowth / Late Stage

Investment Focus Areas

Drug Development

Investment Orientation

Engagement Status

Active

Investor Type

Family Office

Investment Website

Recorded Investments

Private placement financing (co-led) - $50m financing

atai $50m private placement financing
atai Life Sciences

Nov 23, 2020

Series C financing (co-led) - $125m financing round

Date uses press release date.

ATAI closes $125m Series C financing round

Quick Facts

HQ
Abu Dhabi, United Arab Emirates
Website
Visit